These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8529503)

  • 1. Influence of oral sulfonylurea agents on hepatic glucose uptake.
    Kawamori R; Morishima T; Kubota M; Matsuhisa M; Ikeda M; Kamada T
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S109-13. PubMed ID: 8529503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of strict metabolic control on glucose handling by the liver and peripheral tissues in non-insulin-dependent diabetes mellitus.
    Kawamori R; Morishima T; Ikeda M; Kubota M; Kubota M; Kishimoto M; Shiba Y; Matsuhisa M; Kodama M; Watarai T
    Diabetes Res Clin Pract; 1994 Apr; 23(3):155-61. PubMed ID: 7924875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues.
    Mandarino LJ; Gerich JE
    Diabetes Care; 1984; 7 Suppl 1():89-99. PubMed ID: 6376034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes.
    Overkamp D; Volk A; Maerker E; Heide PE; Wahl HG; Rett K; Häring HU
    Diabetes Care; 2002 Nov; 25(11):2065-73. PubMed ID: 12401758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of glimepiride on in vivo insulin action in normal and diabetic rats.
    Sato J; Ohsawa I; Oshida Y; Sato Y; Sakamoto N
    Diabetes Res Clin Pract; 1993; 22(1):3-9. PubMed ID: 8137714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes.
    Müller G; Geisen K
    Horm Metab Res; 1996 Sep; 28(9):469-87. PubMed ID: 8911985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different sensitivity of glucose and amino acid metabolism to insulin in NIDDM.
    Luzi L; Petrides AS; De Fronzo RA
    Diabetes; 1993 Dec; 42(12):1868-77. PubMed ID: 8243833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group.
    Kawamori R; Matsuhisa M; Kinoshita J; Mochizuki K; Niwa M; Arisaka T; Ikeda M; Kubota M; Wada M; Kanda T; Ikebuchi M; Tohdo R; Yamasaki Y
    Diabetes Res Clin Pract; 1998 Jul; 41(1):35-43. PubMed ID: 9768370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Special pharmacology of the new sulfonylurea glimepiride.
    Geisen K
    Arzneimittelforschung; 1988 Aug; 38(8):1120-30. PubMed ID: 2904269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of hyperglycemia on insulin's in vivo effects in type II diabetes.
    Revers RR; Fink R; Griffin J; Olefsky JM; Kolterman OG
    J Clin Invest; 1984 Mar; 73(3):664-72. PubMed ID: 6368585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in glucose metabolism in the elderly patient with diabetes.
    Meneilly GS; Dawson K; Tessier D
    Diabetes Care; 1993 Sep; 16(9):1241-8. PubMed ID: 8404427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic pathways of glucose in skeletal muscle of lean NIDDM patients.
    Kelley DE; Mokan M; Mandarino LJ
    Diabetes Care; 1993 Aug; 16(8):1158-66. PubMed ID: 8375246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects.
    Groop L; Luzi L; Melander A; Groop PH; Ratheiser K; Simonson DC; DeFronzo RA
    Diabetes; 1987 Nov; 36(11):1320-8. PubMed ID: 3117609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of sulfonylureas on hepatic glucose metabolism in type II diabetics.
    Kolterman OG
    Diabetes Metab Rev; 1987 Apr; 3(2):399-414. PubMed ID: 3552528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas.
    Müller G; Satoh Y; Geisen K
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S115-37. PubMed ID: 8529504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic sensitivity to insulin: effects of sulfonylurea drugs.
    Del Prato S; Vigili de Kreutzenberg S; Riccio A; Tiengo A
    Am J Med; 1991 Jun; 90(6A):29S-36S. PubMed ID: 1872301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical profile of glimepiride.
    Draeger E
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S139-46. PubMed ID: 8529506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.